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Background: Previous studies report body-mass index (BMI) and percent weight loss (WL) to have prognostic
significance when treating patients with nasopharyngeal carcinoma (NPC). However, most of these investigations
studied patients treated using different radiotherapeutic techniques. We evaluated the predictive effect of these
two nutrition-related measurements on therapeutic outcome in NPC patients who only received intensity-modulated
radiation therapy (IMRT) as part of their total treatment program.
Methods: We retrospectively studied NPC patients treated with IMRT from January 2006 to February 2012. Cox
proportional hazards was used to test the association of pretreatment BMI (<23 kg/m2 vs. ≥23 kg/m2) and percent
weight loss (≥5 % vs. <5 %) during therapy and related survival rates while controlling for various potential
confounders.
Results: Eighty-one (34 %) of the 238 patients had BMIs ≥23 kg/m2 at pretreatment and 150 (63 %) had significant
(≥5 %) weight loss. Median follow-up time was 41.71 months; median radiotherapy was 7.46 ± 0.77 weeks. Those with
BMIs ≥23 kg/m2 did not have a better 3-year overall survival (p = 0.672), 3-year disease specific survival (p = 0.341),
3-year locoregional free survival (p = 0.281), or 3-year distant metastatic free survival (p = 0.134). Those with significant
WL (≥5 %) did not have worse 3-year clinical endpoints, even after stratifying magnitude of weight loss by BMI category.
In sensitivity test, the adjusted hazard ratio remained statistically insignificant using different cutoffs for BMIs and
percent weight loss.
Conclusions: This study found no significant relationship between BMI and percent weight loss on survival of NPC
patients receiving IMRT based therapy. Further studies might want to consider other nutrition related factors as
prognostic indicators when studying the correlate between malnutrition and survival in this population.
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Nasopharyngeal carcinoma(NPC) is a head and neck
epithelial malignancy with a striking racial/ethnic distri-
bution and endemic to Southeast Asia and southern
China. It differs from non-nasophayngeal head and neck
squamous cell carcinoma in several ways, including its* Correspondence: asoschang@gmail.com
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radio- and chemo-sensitivity, and a greater propensity
for presenting as locoregional advanced disease at diag-
nosis [1, 2]. Its treatment has been enhanced greatly by
intensity-modulated radiotherapy (IMRT), which has
improved locoregional control but not distant metastasis
[3]. The IMRT technique might be improved by the
identification of predictors of poorer prognosis among
these patients. Although several promising molecular
targets have been found to predict treatment failure ine distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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and are not routinely tested by most medical institutes.
Malnutrition has been significantly and directly associ-
ated with overall survival among cancer patients [4].
Body mass index (BMI) and weight change during ther-
apy, two nutrition-related factors, have been found to
have prognostic significance in NPC. In particular, sev-
eral studies have reported low pretreatment BMI and a
high weight loss during therapy to be independently and
significantly associated with poorer survival independent
of several established factors [5–7]. However, the sub-
jects of these studies were patients treated with diverse
radiotherapeutic techniques combined together in one
study group. The techniques used to treat NPC change
over time and vary regionally, and thus it may be neces-
sary to reevaluate the prognostic values of certain factors
when one technique replaces others as a preferred
means of treatment. In this study, we wanted to find out
if two previously reported anthropometric measure-
ments, pretreatment BMI and weight loss, remained pre-
dictive of prognosis in NPC patients being treated in a
program using IMRT based therapy. To do this, we
retrospectively recruited 238 consecutive patients with
nasopharyngeal carcinoma treated with IMRT in a single
medical institute, and studied the effect of pretreatment
BMI and weight loss during therapy on overall survival,
disease-specific survival, locoregional free survival, and
distant metastasis free survival, controlling for various
related factors.
Materials and methods
Patients and data collection
The protocol for this study was approved by the Institu-
tional Review Board of Kaohsiung Veterans General Hos-
pital, Taiwan. We enrolled 260 consecutive patients newly
diagnosed with nasopharyngeal carcinoma at Kaohsiung
Veterans General Hospital from January 2006 to February
2012. All patients had received routine magnetic reson-
ance imaging for tumor staging. Patients were excluded if
they were below 18 years old (n = 1), were classified as
having a World Health Organization (WHO) classification
type one lesion (n = 5), or were found to have distant me-
tastasis at initial diagnosis or had any other malignancy
treated with radiotherapy previously or concomitantly
(n = 16). After exclusion, we were left with a total of 238
patients to include in our analysis.
Nutritional data
Pretreatment weight was measured on day one of radio-
therapy for patients receiving radiotherapy alone or
concurrent radiotherapy or on day one chemotherapy
for patients receiving induction chemotherapy prior to
radiotherapy. The post-treatment weight was measured
one month following treatment. A critical weight losswas defined as weight loss greater than 5 %, as of this
magnitude is considered to indicate possible nutritional
deterioration [8, 9]. Baseline BMI prior to radiotherapy
was calculated by dividing the pretreatment weight (kgs)
by the square of height (meters). The patients were
further divided into two groups using the cut-off point,
23 kg/m2, a WHO classification for overweightness and
obesity for Asians [10].
Radiotherapy
Before treatment, all patients were immobilized with a
thermoplastic head and shoulder mask, and CT simula-
tion was performed following standard procedures. All
patients were treated with IMRT technique. The total
prescribed dose was 70–76 Gy to the gross tumor volume
of nasopharynx (GTVnx) and the gross tumor volume of
positive neck lymph nodes (GTVnd), 60–66 Gy to the
high risk region as clinical target volume 1 (CTV 1), and
50–60 Gy to low risk region as CTV2. The radiation given
to both gross tumor and regional lymphatics was adminis-
trated in a conventional fractionated dose of 1.6–2 Gy,
one fraction per day, five days per week.
Chemotherapy
Our institution recommends radiotherapy only for pa-
tients in stages I–II, and concurrent chemoradiotherapy
for those in stages III–IVB. Induction chemotherapy was
administered to patients with T4 and/or N3 disease,
whereas adjuvant chemotherapy was administered to pa-
tients with residual disease of high incidence for distant
metastasis, including N3, T3/T4 with multiple neck
lymph nodes metastasis, multiple neck lymphadenop-
athy with one of node size > 4 cm [11]. Induction and
adjuvant chemotherapy bolus injections of 80 mg/m2 of
cisplatin on day one were followed by 1000 mg/m2 of
fluorouracil administered daily by 96-h continuous infu-
sion from Day 2 to Day 5 every 3 to 4 weeks. The con-
current chemotherapy was prescribed for 188 (79 %)
patients at a dosage of 80 to 100 mg/m2 of cisplatin on
Day one, Day 22, and Day 43 or 30 mg/m2 of cisplatin
every week, for 6–8 cycles. After completion of treat-
ment, further follow-up assessments were performed at
3-month intervals for the first three years. The intervals
gradually increased to every four months, biannually to
annually, thereafter.
Clinical end points
Clinical endpoints were 3-year overall survival, disease
specific survival, any recurrence or distant metastasis.
Overall survival was defined as the time that had elapsed
between the diagnosis and the date of death from any
cause or three years if patient was still alive at the end of
the study period. Disease specific survival, locoregional
free survival, and distant metastasis free survival were
Table 1 Clinical data of 238 nasopharyngeal carcinoma patients
Pre-treatment BMI, kg/m2
Variable All <23 (N = 81) ≥23 (N = 157) p
Age, y 50.26 ± 11.82 49.02 ± 12.84 50.09 ± 11.24 0.246
Sex (%) <0.001
male 169(71.0) 45(55.6) 124(79.0)
female 69(29.0) 36(44.4) 33(21.0)
Smoke (%) 0.106
No 160(67.2) 60(74.1) 100(63.7)
Yes 78(32.8) 21(25.9) 57(36.3)
CCIS (%) 0.742
0 184(77.3) 64(79.0) 120(76.4)
1 32(13.4) 9(11.1) 23(14.6)
≥2 22(9.2) 8(9.9) 14(8.9)
Histology type 0.082
NUC 214(89.9) 69(85.2) 145(92.4)
NDC 24(10.1) 12(14.8) 12(7.6)
T classification (%) 0.253
T1/T2 121(50.8) 37(45.7) 84(53.5)
T3/T4 117(49.2) 44(54.3) 73(46.5)
N classification (%) 0.779
N0/N1 62(26.1) 22(27.2) 40(25.5)
N2/N3 176(73.9) 59(72.8) 117(74.5)
AJCC Stage (%) 0.775
Stage 1/2 36(15.1) 13(16.0) 23(14.6)
Stage 3/4 202(84.9) 68(84.0) 134(85.4)
Treatment arm (%) 0.592
RT alone 41(17.2) 15(18.5) 26(16.6)
CCRT alone 93(39.1) 28(34.6) 65(41.4)
RT/CCRT + CT 104(43.7) 38(46.9) 66(42.0)
BWL (%) 0.003
<5 % 88(37.0) 41(50.6) 47(29.9)
≥5 % 150(63.0) 40(49.4) 110(70.1)
Education level (%) 0.97
Low 113(47.5) 39(48.1) 74(47.1)
Medium 70(29.4) 23(28.4) 47(29.9)
High 55(23.1) 19(23.5) 36(22.9)
RT duration 7.46 ± 0.77 7.58 ± 0.80 7.40 ± 0.75 0.091
Hemoglobin 13.85 ± 1.77 13.28 ± 1.66 14.15 ± 1.75 0.001
CCIS Charlson Comorbidity Index Score; NUC nonkeratinizing undifferentiated
carcinoma; NDC nonkeratinizing differentiated carcinoma; BMI body mass
index; BWL body weight loss; RT radiotherapy; CT chemotherapy; CCRT
concurrent chemoradiotherapy
Values are numbers (percentage)
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ure free survival (FFS) was defined as the time that had
elapsed between the initiation of radiotherapy and the
date of recurrence and/or metastasis or three years if pa-
tient was free of disease. Patients who were lost to
follow-up within 3 years were censored at their last date
of follow-up.
Statistical analysis
All statistical operations were performing using the SPSS
ver. 15 (SPSS Inc., Chicago, IL, USA). Pearson’s chi-
square tests were used to explore the differences be-
tween categorical variables and t-test for continuous
variables. Overall survival, disease specific survival, dis-
tant metastasis free survival, and locoregional free sur-
vival were generated according to the methods of
Kaplan and Meier. Differences between survival curves
were compared using the log-rank test. The prognostic
influence of pretreatment BMI and weight loss during
therapy were assessed using Cox proportional hazards
multivariate model after adjusting for patients’ character-
istics, including age, gender, AJCC T classification, AJCC
N classification, category of Charlson Comorbidity Index
Score, smoking status, education level (low being less than
junior high school, medium being high school level, and
high being one year or more of college), treatment modal-
ities (RT alone, CCRT, RT/CCRT +CT), and hemoglobin
level. A two-sided p-value < 0.05 was considered significant.
To explore whether the results would hold against changes
in the cut-off values, we conducted a sensitivity analysis
utilizing three other combinations of widely used cutoffs
for BMI (kg/m2) and critical weight loss (%) [6, 8, 12]: (1)
23 kg/m2 and 10 % (2) 25 kg/m2 and 5 %, and (3) 25 kg/m2
and 10 %.
Results
Demographic data and clinical characteristics
Patient characteristics are described in Table 1. In total,
there were 238 patients predominately male (71 %). The
median age was 50.26 ± 11.82 years. Two hundred and
two patients (84.9 %) were categorized as having stages
III and IVA/IVB disease based on the 7th UICC/AJCC
staging system. Mean BMI was 24.75 ± 4.19. Eighty-one
patients (34 %) had BMIs below 23 kg/m2, and 157
(66 %) had BMIs greater than 23 kg/m2. The average
weight loss from first radiotherapy to one month post-
treatment was 7.85 ± 4.32 kgs. Eighty-eight patients
(37 %) had weight loss <5 % and 150 (63 %) had weight
loss ≥5 %. A greater proportion of the patients with pre-
treatment BMI ≥ 23 kg/m2 were more likely to have high
weight loss. Subjects with pretreatment BMIs ≥23 kg/m2
had higher serum hemoglobin (p = 0.001). However, no
significant differences were found in either category of
pretreatment BMI regardless of CCIS group, treatmentarm, or education level. Forty-one patients (17.2 %) had
radiotherapy only, and the rest received combined mo-
dality treatment. The median duration of radiotherapy
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was 41.71 months.
Univariate survival analysis
As can be seen in Table 2, neither pretreatment BMI nor
percent weight loss was significantly associated with over-
all survival, disease specific survival, distant metastasis freeTable 2 Univariate analyses of risk factors for 3-year LRFS, DMFS, DS
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RT alone 93.8 86.9
CCRT alone 91.8 94.9
RT/CCRT + CT 85.4 84.2
BWL during RT 0.111
≥5 % 100.0 92.7




Abbreviations: LRFS locoregional-free survival; DMFS distant metastasis-free survival; Dsurvival, or locoregional free survival. In the 157 NPC
patients with BMIs ≥ 23, those with weight loss < 5 %
had no survival benefit in overall survival and failure-free
survival (Fig. 1). Similarly, percent weight loss had no im-
pact on the survival of 81 NPC patients with BMIs <23
(Fig. 2). Comorbidity was associated with lower three-year
overall survival (p = 0.025) and locoregional free survivalS, and OS rates





































SS disease-specific survival; OS overall survival. Other abbreviations as in Table 1
Fig. 1 OS and FFS for 157 NPC patients with BMI ≥ 23. a Patients with weight loss greater than 5 % did not have a worse 3-year overall survival
(p = 0.267). b There was no difference with respect to the 3-year failure free survival between the two groups (p = 0.315)
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classification disease had poorer three-year disease specific
survival (p = 0.024).
Multivariate survival analysis
Multivariate analysis also showed that pretreatment BMI
and percentage of weight loss were not associated with
all-cause or cause-specific mortality (Table 3 and Table 4).
Still after adjustment for cofounders, multivariate analysis
revealed a significant difference in three-year overall sur-
vival between patients with CCISs ≥2 and those without
comorbidity (hazard ratio [HR], 3.043 [95 % confidence
interval {CI}, 1.27–7.31; p = 0.013]) and between patients
with high education levels and those low education level
(0.360, [95 % CI, 0.13–0.99; p = 0.047]). In addition,
compared to patients without comorbidities, those with
CCIS = 1 tended to have locoregional recurrence (4.264,
[95 % CI, 1.56–11.65; p = 0.005]). The results remainedFig. 2 OS and FFS for 81 NPC patients with BMI < 23. a Patients with weig
overall survival (p = 0.279). b The difference of 3-year failure-free survival bestatistically insignificant after a sensitivity analysis using
different cutoffs (Additional file 1: Appendix S1). In sum-
mary, significant weight loss did not confer a worse 3-year
survival rate after stratifying for magnitude of weight loss
by BMI category.
Discussion
This study did not find an association between pretreat-
ment BMI or magnitude of weight loss and clinical out-
come in NPC patients receiving IMRT-based therapy.
To the best of our knowledge, this study represents first
study to investigate the effect of these parameters on in
NPC patients receiving IMRT as the only radiotherapy
in their treatment programs.
Previous studies have found both weight loss and BMI
to be predictive of survival. Van Bokhorst-de van der
Schuer et al. [13] reported that in patients with head and
neck cancer (HNC) there was a direct associationht loss percentage greater than 5 % demonstrated no superior 3-year
tween the two groups was not statistically significant (p = 0.054)
Table 3 Multivariate analysis for OS and DSS for all patients
OS DSS
Variable Comparison p HR (95 % CI) p HR (95 % CI)
Age Young vs. old 0.141 1.715(0.84–3.52) 0.204 1.756(0.74–4.19)
Sex Male vs. female 0.786 1.100(0.55–2.20) 0.194 1.727(0.76–3.94)
preT BMI <23 kg/m2 vs. ≥23 kg/m2 0.672 1.164(0.58–2.36) 0.341 0.670(0.29–1.53)
Education level Low vs. Medium 0.427 0.731(0.34–1.58) 0.807 1.122(0.44–2.84)
Low vs. high 0.047 0.360(0.13–0.99) 0.199 0.368(0.08–1.69)
CCIS 0 vs. 1 0.852 0.911(0.34–2.42) 0.660 1.282(0.42–3.88)
0 vs. ≥2 0.013 3.043(1.27–7.31) 0.318 1.936(0.53–7.08)
T classification Early vs. late 0.191 1.563(0.80–3.06) 0.706 1.171(0.52–2.66)
N classification Early vs. late 0.331 1.539(0.65–3.67) 0.128 3.206(0.71–14.40)
Treatment RT vs. CCRT 0.595 1.325(0.47–3.74) 0.468 0.612(0.16–2.30)
RT vs. RT/CCRT + CT 0.655 1.276(0.44–3.73) 0.840 1.132(0.34–3.79)
BWL percentage <5 % vs. ≥5 % 0.087 1.910(0.91–4.01) 0.232 1.746(0.70–4.36)
Abbreviations: HR hazard ratio; CI confidence interval. Other abbreviations as in Tables 1 and 2
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larly, Capuano et al. [14] and Langius et al. [9] have re-
ported that weight loss during (chemo)radiotherapy is a
major predictor in this patient population. With regard
to BMI, Bhaskaran et al. [15] in a robust study of the re-
lation between BMI and a larger number of different
cancers but not NPC, found that it had various levels of
impact on the incidence and survival of several site-
specific cancers. Park et al. [16] later observed a significant
association between a higher BMI and longer survival in
Korean patients with HNC and esophageal cancer. Pai
et al. [17] and Ottosson et al. [12] reported similar findings
for Chinese and Swedish patients with HNC.
NPC differs from HNC with regard to etiology, geo-
graphic distribution, racial distribution, and patient char-
acteristics. In retrospective studies, Qiu et al. [18] andTable 4 Multivariate analysis for LRFS and DMFS for all patients
LRFS
Variable Comparison p
Age Young vs. old 0.085
Sex Male vs. female 0.531
preT BMI <23 kg/m2 vs. ≥23 kg/m2 0.281
Education level Low vs. Medium 0.161
Low vs. high 0.190
CCIS 0 vs. 1 0.005
0 vs. ≥2 0.585
T classification Early vs. late 0.444
N classification Early vs. late 0.998
Treatment RT vs. CCRT 0.592
RT vs. RT/CCRT + CT 0.353
BWL percentage <5 % vs. ≥5 % 0.284
Abbreviations: HR hazard ratio; CI confidence interval. Other abbreviations as in TabNg et al. [19] reported a high prevalence of severe
weight loss in NPC patients during radiotherapy, and
Shen et al. [5] reported that such weight loss had a nega-
tive impact on prognosis in this population regardless of
BMI category. One prospective study of NPC patients by
Huang et al.[6] and a retrospective study Shen et al. [7]
focusing on the pretreatment lifestyle behaviors and
clinical outcome in NPC patients both found significant
associations between BMI category and prognosis of
locoregional advanced NPC. However, one problem with
these investigations is that the radiation techniques used
within each of their studies differed [5–7, 18, 19].
Our study did not find an association between percent
weight loss or pretreatment BMI with prognosis in NPC.
Our study was different from those mentioned above in
that we studied NPC patients receiving IMRT basedDMFS













les 1 and 2
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factors, so there may be several reasons for the differ-
ence in our findings and theirs. The first is that IMRT,
unlike conventional 2D and conformational 3D radiation
techniques, makes it more likely that the patient will
complete his or her treatment plan within the planned
time without interruption. IMRT can do this because it
delivers a highly conformal dose to an irregular-shaped
tumor making it possible to lower integral dose to or-
gans at risk and normal critical tissues [20]. This re-
duced toxicity is responsible for IMRT’s improvements
in radiotherapy-related xerostomia as well as its reduc-
tion of many of the most dramatic acute side effects of
radiotherapy, including mucositis, pharyngitis, cutaneous
desquamation of neck, and dysgusia, as it can be per-
formed with tightly planned dose constraints [20, 21].
This reduced toxicity can alleviate some of the negative
dietary symptoms that can lead to malnutrition and de-
bilitation, when IMRT treatment is coupled with the aid
of antiemetic agents, oral analgesics, and frequent oral
rinsing [20, 21].
Furthermore, the reduced toxicity that comes with the
use of IMRT may lessen the number and severity of
head and neck symptoms and improve quality of life, ac-
cording to Fang et al. [22, 23], who compared the effect
of various radiotherapeutic tecnhiques on quality of life.
Such improvements are believed to contribute to fewer
treatment interruptions and better therapeutic tolerance.
In the present study, all the patients completed the ther-
apy within amount of time planned without interruption.
It is possible that the uninterrupted completion of the
treatment program and the reduction of adverse nutri-
tional effects made possible by IMRT translated into bet-
ter clinical outcomes for our patients, even in those with
greater weight loss and lower pretreatment BMIs [24, 25].
Apart from the technical superiority of IMRT, the sec-
ond reason our findings are different from the previous
studies could be related to the possibility that pretreat-
ment BMI or weight loss may not be adequate indicators
of malnutrition in this patient group being treated with
IMRT. Most of the HNC and NPC studies mentioned
above have used BMI and weight loss as surrogates of
malnutrition [5–7, 9, 12, 14, 17–19]. However, some stud-
ies have associated impairment of several other nutritional
factors with poorer prognosis in NPC patients [26–29]
and with quality of life in other populations [30, 31]. We
assumed that because radiotherapy causes similar adverse
responses in HNC and NPC patients, BMI and weight loss
should have prognostic significance. However we did not
find them to have this prognostic significance in our study.
BMI and weight loss may not be the best surrogates of
malnutrition. Changes in body composition such as fat-
free mass, especially muscle mass, and body fat mass, ra-
ther than pure total body weight may be more relevantto survival. For example, in their studies of patients
treated for cancers of the respiratory and digastric tracts,
Prado et al. [32] and Martin et al. [33] reported that low
muscle mass (sacropenia) predicted poor survival and
poor quality of life and survival independently of other
covariates. In addition, muscle mass is known to vary
within each BMI category, so cancer patients in any cat-
egory of BMI may appear well or unwell regardless of
percent weight loss [32–34]. As a consequence, consid-
ering the discrepancies between the two traditional an-
thropometric parameters and body composition in cancer
patients, compartments of body composition might be
more suitable indices of malnutrition for NPC population.
The prescription of nutritional supplementation, par-
ticular for cancer patients, has recently attracted the at-
tention of the physicians treating them. Although there
is consistent evidence that the provision of nutrients for
cancer populations undergoing treatment predicts a less
weight loss, fewer treatment-related complications, and a
better quality of life [35], the impact of nutrition support
on survival outcome remains controversial. Fearon et al.
[36] reported a correlation between an effective nutrition
intervention and better survival and attributed it to the
maintenance of muscle mass. In contrast, Rabinovitch et al.
[37] observed that patients with advanced-staged HNC re-
ceiving nutritional support prior to (chemo)radiotherapy
had poorer locoregional control and overall survival. The
current study lacked detailed information on the nutrients
being used by the patients. Therefore, further research
may be needed to determine the prognostic significance
of nutritional intervention on NPC survival.
This study has some limitations. One limitation is that
it is a hospital-based retrospective study with a small
sample size. Another limitation is that we did not take
into consideration the impact of chemotherapy on the
nutritional measures and the resulting effect on prognosis.
Another limitation was that BMI and weight loss measure-
ment were limited to pre-treatment and treatment pe-
riods. Those measures can change after treatment and
affect eventual health outcomes. Still another limitation is
that we only used the traditionally studied BMI and per-
cent weight loss as surrogates of malnutrition. We did not
use other nutrition related factors to assess nutritional sta-
tus, so it is not certain whether or not or to what extent
our patients were indeed malnourished. In addition, it is
worth noting that not all variables with significant p-value
after a multiple testing truly indicate a significant differ-
ence. Due to the small number of samples and the un-
equal distribution of sample sizes, the significance of these
variables should be interpreted with caution.
Conclusions
This study found no significant relationship between
BMI and percent weight loss on survival of NPC patients
Lin et al. Radiation Oncology  (2015) 10:136 Page 8 of 9being treated with IMRT as part of their treatment pro-
gram, possibly suggesting the use of IMRT reduces the
importance of the traditional predictors of prognosis.
Further studies may be needed to determine whether
other nutrition related factors might better indicate
nutritional state and correlate with survival in NPC
patients.
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